【摘要】 目的本文主要研究过表达S期激酶相关蛋白2(Skp2)能否影响曲格列酮(TRG)对乳腺癌细胞的敏感性,致力于发展一种新的药物来提高患者的生存率,最终达到治愈的目的。方法荧光报告基因方法观察过氧化物酶体增殖物激活受体(PPAR)γ型转录活性的变化;流式细胞和CCK-8法研究Skp2过表达影响TRG对乳腺癌细胞生长和凋亡的改变。结果 Skp2过表达能抑制PPARγ的活性,耐受TRG对乳腺癌细胞生长和凋亡的影响。结论 Skp2过表达的乳腺癌细胞能耐受TRG的敏感性,因此通过下调Skp2可能会增强TRG对乳腺癌细胞的生长抑制。更多还原

【Abstract】 Objective To investigate the effects of Skp2 overexpression on the sensitivity of troglitazone(TRG)in breast cancer cells and to devote to develop a novel drug for increasing the patient survival rate and eventually reaching the cure goal.MethodsThe transcription activities of PPARγwere analyzed on peroxisome proliferators response element(PPRE)luciferase reporter.The flow cytometry analysis and CCK-8assay were adopted to study that overexpression of Skp2 was associated with resistance to TRG-mediated inhibition growth and apoptosis of breast cancer cells.Results Our study found that overexpression of Skp2 inhibited the transcriptional activity of the endogenous PPARγand resisted to TRG-mediated inhibition growth and apoptosis of breast cancer cells.Conclusion Overexpressed Skp2 breast cancer cells is able to be resistant to TRG-induced sensitivity of breast cancer cells.Furthermore down-regulating Skp2 will significantly enhance the growth inhibition of TRG on breast cancer cells.更多还原